The following drug information is obtained from various newswires, published
medical journal articles, and medical conference presentations.
Lovenox (enoxaparin sodium) Injection has been approved for use
in the prevention of deep vein thrombosis (DVT) which may lead to
pulmonary embolism (blood clots in the lung) in patients undergoing
abdominal surgery who are at risk for thromboembolic
Surgical patients at risk include those who are over 40 years of
age, obese, undergoing surgery with general anesthesia longer than
30 minutes, or who have additional risk factors such as a malignant
tumor or a history of deep vein thrombosis or pulmonary
A new indication for Lovenox was approved in March of 1998. This
indication is for the prevention of ischemic complications of
unstable angina and non-Q-wave myocardial infarction (heart attack)
when concurrently administered with aspirin. Unstable angina is a
serious condition that can lead to heart attack or death.
Deep vein thrombosis is the formation of blood clots which may
lead to pulmonary embolism. Pulmonary embolism occurs when a clot
circulates and lodges in the lungs, and can cause sudden death.
Venous thromboembolic disease is responsible for more than 400,000
hospitalizations and up to 200,000 deaths each year in the U.S.